These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27465554)

  • 1. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
    Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
    Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
    Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
    Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
    Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
    Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy.
    Kurtul N; Eroglu C; Unal D; Tasdemir EA; Orhan O; Zararsiz G; Baran M; Kaplan B; Kontas O
    Asian Pac J Cancer Prev; 2014; 15(20):8911-6. PubMed ID: 25374228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
    Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
    Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
    Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
    Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
    Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S
    Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.